Theraclone Sciences Inc.
28Patents
28Active
28Granted
50Portfolio score
Filing activity: Nov 12, 2008 → Jun 5, 2024 · 7 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9051362B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 14 | Active |
| US9464131B2 | Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody | Chemistry; Metallurgy | 14 | Active |
| US10087239B2 | Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody | Chemistry; Metallurgy | 12 | Active |
| US8916160B2 | Compositions and methods for the therapy and diagnosis of influenza | Physics | 8 | Active |
| US8057796B2 | Compositions and methods for the therapy and diagnosis of influenza | Chemistry; Metallurgy | 6 | Active |
| US8114402B2 | Compositions and methods for the therapy and diagnosis of influenza | Chemistry; Metallurgy | 4 | Active |
| US8329188B2 | Human M2e peptide immunogens | Emerging Cross-Sectional Technologies | 2 | Active |
| US8460671B2 | Compositions and methods for the therapy and diagnosis of influenza | Chemistry; Metallurgy | 2 | Active |
| US8900590B2 | Anti-hemagglutinin antibody compositions and methods of use thereof | Physics | 2 | Active |
| US8268309B2 | Compositions and methods for the therapy and diagnosis of cytomegalovirus | Physics | 2 | Active |
| US11319362B2 | Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies | Chemistry; Metallurgy | 2 | Active |
| US7982012B2 | Compositions and methods for the therapy and diagnosis of cytomegalovirus | Physics | 1 | Active |
| US8974788B2 | Compositions and methods for the therapy and diagnosis of influenza | Physics | 1 | Active |
| US8609101B2 | Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies | Emerging Cross-Sectional Technologies | 1 | Active |
| US8858948B2 | Compositions and methods for the therapy and diagnosis of influenza | Chemistry; Metallurgy | 1 | Active |
| US8852594B2 | Compositions and methods for the therapy and diagnosis of cytomegalovirus infections | Physics | 1 | Active |
| US8822651B2 | Human rhinovirus (HRV) antibodies | Chemistry; Metallurgy | 0 | Active |
| US10865234B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US12312396B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US11584789B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US11845789B2 | Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies | Chemistry; Metallurgy | 0 | Active |
| US9920111B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US8932597B2 | Human M2e peptide immunogens | Emerging Cross-Sectional Technologies | 0 | Active |
| US12018067B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US10407493B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.